Peptides DB
Research-centric peptide and protocol reference hub
Study 18 of 57Semaglutide literatureeuropepmc · Observational2026

<i>Parasutterella excrementihominis</i> is associated with attenuated metabolic improvements during obesity therapy in humans.

Parasutterella excrementihominis abundance decreased during weight loss therapy, correlating with improved insulin sensitivity, but its role in weight management remains uncertain.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
13
Preclinical
34
Observational · this one
2
Open-label
2
Randomised
6
Reviews

Summary and findings

This study measured the abundance of Parasutterella excrementihominis in 215 human subjects undergoing a non-surgical obesity therapy program. The study found that P. excrementihominis abundance decreased during the weight reduction phase and was positively correlated with improvements in insulin sensitivity. No treatment claims are made regarding the implications of these findings.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as europepmc supplied them

Alterations in the composition and function of the gut microbiome are important in obesity and type 2 diabetes development. Using our cross-sectional FoCus cohort, we recently found <i>Parasutterella</i> species were increased in human obesity and type 2 diabetes and linked to abnormalities in triglyceride metabolism and L-cysteine homeostasis, the latter being important for beta-cell function. To gain further insights, we now quantified gut <i>Parasutterella excrementihominis</i> by qPCR in <i>n </i>= 215 human subjects during an interdisciplinary non-surgical obesity therapy program consisting of an initial weight-reduction phase (weeks 1-12) followed by a weight-maintenance phase (weeks 13-26). <i>P. excrementihominis</i> abundance was significantly reduced during the weight reduction phase. While baseline abundance levels did not predict the success of weight-reduction, they were inversely associated with C-reactive-protein improvements. Interestingly, the decrease in <i>P. excrementihominis</i> abundance during the weight reduction phase was positively correlated with improvements in insulin sensitivity throughout the overall obesity intervention. Regarding the weight maintenance phase, a re-increase of <i>P. excrementihominis</i> abundance was significantly associated with weight regain. In summary, our data suggest that <i>P. excrementihominis</i> attenuates metabolic and inflammatory improvements in obese human subjects under therapy and highlight a potential role of this bacterial species in metabolic adaptation during weight loss interventions.

Elsewhere in the Semaglutide corpus

DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.reviewBWeight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort studybiorxiv-preprint · At 16 weeks, NMGP users lost 8.3% of their baseline weight.HumanBSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.HumanBA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.Renal failure · 2026 · n=875 · AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).HumanBFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.HumanBOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.Human